Search Results

281 results

  1. CORESTA Meeting, Agronomy/Phytopathology, 2021, Online, AP 33

    Identification and functional characterization of the pale yellow gene in tobacco

    GRUNDMANN L.(1); PRAMOD S.(2); ADAMS A.(2); FREDERICK J.(2); KAENEL A.(1); NOLL G.(1); XU D.(2); PRUEFER D.(1); LUSSO M.(2)
    (1) Fraunhofer IME, Münster, Germany; (2) Altria Client Services, Richmond, VA, U.S.A.
    The pale yellow (PY) trait in tobacco (Nicotiana tabacum L.) was first described in 1969 and was found to be controlled by a single dominant gene. Plants containing a PY gene show accelerated chlorophyll breakdown compared to wild type plants. In...
  2. CORESTA Meeting, Agronomy/Phytopathology, 2021, Online, AP 50

    Genetic mapping of a novel low-anatabine gene mutation in tobacco (Nicotiana tabacum L.)

    KUDITHIPUDI C.; HART F.R.
    Altria Client Services LLC, Research Development & Regulatory Affairs, Richmond, VA, U.S.A.
    Anatabine is a minor alkaloid found in tobacco and constitutes about 3 % of the total alkaloids. It is a precursor for N-nitrosoanatabine (NAT), one of four tobacco-specific nitrosamines (TSNAs) found in cured tobacco leaf. Depending on the...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, NAM 00

    Advancing new alternative methods for tobacco harm reduction

    LEE K.M.(1); BELL S.(2)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Integrated Laboratory Systems (ILS), Morrisville, NC, U.S.A.
    New approach methodologies (NAMs) represent in vitro and in silico or computational methodologies, an emerging set of chemical safety assessment tools without needing additional in vivo animal testing. This virtual symposium introduces the current...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 01

    Development of consumer-reported outcome measure (CROM) standards for the tobacco industry with respect to psychometric CROM using a consortium-based approach: methodology and scope

    McCAFFREY S.(1) on behalf of the CORESTA CROM Task Force (WG02): AFOLALU E.(2); BLACK R.(1); CHREA C.(2); CURTIN G.(3); GILES L.(4); NISHIHARA D.(4); PRASAD K.(5); SARKAR M.(6); SHETTY M.(5)
    (1) JUUL Labs, Inc., San Francisco, CA, U.S.A.; (2) Philip Morris Products S.A., Neuchâtel, Switzerland; (3) RAI Services Company, Winston-Salem, NC, U.S.A.; (4) JT International S.A., Geneva, Switzerland; (5) British American Tobacco, Southampton, U.K.; (6) Altria Client Services, Richmond, VA, U.S.A.
    In November 2018, CORESTA approved the formation of a new Task Force (TF) to establish best practices and guidelines for the integration of consumer-reported outcome measures (CROM) in tobacco regulatory research. The primary objective of the CROM TF...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 02

    Descriptive consumer reported outcome measures and definitions in tobacco and nicotine research: a consensus approach

    WEI L.(1) on behalf of the CROM Task Force: CLERC E.(2); SHETTY M.(3); CHREA C.(2); PRASAD K.(3); SARKAR M.(1)
    (1) Altria Client Services LLC, Richmond, Virginia, U.S.A.; (2) Philip Morris International, Neuchâtel, Switzerland; (3) British American Tobacco, Southampton, U.K.
    The Consumer Reported Outcome Measures (CROM) Consortium Task Force (TF), consisting of academic researchers and members from various tobacco companies, was formed within the Cooperation Centre for Scientific Research Relative to Tobacco (CORESTA) in...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 28 (also presented at TSRC 2021)

    Compound identification process for GC-MS non-targeted analysis of JUUL aerosol using a custom mass spectral library

    JEONG L.N.(1); NOE M.R.(2); SHAH N.H.(2); CHAKRABORTY S.(2); MILLER IV J.H.(2); GILLMAN I.G.(1)
    (1) JUUL Labs, Inc., Washington, D.C., U.S.A.; (2) Altria Client Services, LLC, Richmond, VA, U.S.A. (a Service Provider to JUUL Labs, Inc.)
    The US Food and Drug Administration (FDA) Premarket Tobacco Product Application (PMTA) guidance for electronic nicotine delivery systems (ENDS) recommends that applicants evaluate unique constituents in the aerosol of ENDS products for potential...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 38

    In vitro to in vivo extrapolation (IVIVE) for evaluating exposure and health impacts of e-vapor products using ingredient and mixture in vitro data

    ZHANG Jingjie(1); CHANG X.(2); HINES D.(2); BELL S.(2); LEE K.M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Integrated Laboratory Systems (ILS), RTP, NC, U.S.A.
    In Vitro to In Vivo Extrapolation (IVIVE) uses reverse dosimetry to translate in vitro bioactivity data to clinically relevant exposure metrics. This study applies the IVIVE approach to e-vapor products using reported in vitro cytotoxicity data of...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 43

    Quantitative analysis of NNN in plasma: a suitable alternative to urinary determination to assess the exposure to this important toxicant

    PLUYM N.(1); SIBUL F.(1); JIN X.(2); EDMISTON J.(2); SARKAR M.(2); SCHERER G.(1); SCHERER M.(1)
    (1) ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany; (2) Altria Client Services LLC, Center for Research & Technology, Richmond, VA, U.S.A.
    N-Nitrosonornicotine (NNN) is classified as a Group 1 carcinogen by the International Agency for Research on Cancer. Urinary NNN has often been used as a biomarker of exposure. However, urinary NNN excretion is highly variable, possibly due to...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 50

    In vivo genotoxicity testing of aerosols generated from JUUL ENDS products

    LALONDE G.(1); ZHANG Jingjie(2); JALIGAMA S.(3); GUPTA A.(3); PSURNY E.(3); LEE K.M.(2); DOSHI U.(2); YAO J.(1)
    (1) JUUL Labs, Inc., San Francisco, CA, U.S.A.; (2) Altria Client Services, LLC, Richmond, VA, U.S.A. (a Service Provider to Juul Labs, Inc.); (3) Battelle Memorial Institute, West Jefferson, OH, U.S.A.
    We evaluated the in vivo genotoxicity potential of aerosols generated from two commercial nicotine electronic delivery systems (ENDS) products, P1 and P2, with a combined micronucleus (MN) and comet study design based on OECD TG 474 and...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 57

    Nonclinical toxicity assessment of oral tobacco-derived nicotine products: I. Framework

    ZHANG M.; SMITH C.; MORGAN R.; DOSHI U.; KUMAR A.; LEE K.M.
    Altria Client Services LLC, Richmond, VA, U.S.A.
    There is an increasing acknowledgement of a broad "continuum of risk" among tobacco products, with combustible cigarettes at the highest end and non-combustible products toward the lower end of health risk. The oral tobacco-derived nicotine (OTDN)...